The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

BACKGROUND: Anlotinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with non-small cell lung cancer (NSCLC) in the ALTER0303 trial. The status of epidermal growth factor receptor (EGFR) mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yizhuo, Wang, Qiming, Zhang, Li, Shi, Jianhua, Wang, Zhehai, Cheng, Ying, He, Jianxing, Shi, Yuankai, Chen, Weiqiang, Luo, Yi, Wu, Lin, Wang, Xiuwen, Nan, Kejun, Jin, Faguang, Dong, Jian, Li, Baolan, Yamaguchi, Fumihiro, Breadner, Daniel, Nagano, Tatsuya, Tanaka, Fumihiro, Husain, Hatim, Li, Kai, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186169/
https://www.ncbi.nlm.nih.gov/pubmed/35693290
http://dx.doi.org/10.21037/tlcr-22-320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186169/
https://www.ncbi.nlm.nih.gov/pubmed/35693290
http://dx.doi.org/10.21037/tlcr-22-320

Ejemplares similares